Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-$10 bln U.S. battle for Britain's Morrisons heads for auction

Wed, 08th Sep 2021 07:49

* Morrisons agreed CD&R's 7 bln stg offer last month

* Rival suitor Fortress considering options

* All parties talking to Takeover Panel regarding auction

* Morrisons shares trading above CD&R's offer
(Adds detail, shares)

By James Davey

LONDON, Sept 8 (Reuters) - The $10 billion takeover battle
for British supermarket group Morrisons between two U.S.
private equity groups looks set to be decided by a rarely used
auction process.

Morrisons said on Wednesday it was in talks with Clayton,
Dubilier & Rice (CD&R), Fortress Investment Group and Britain's
takeover regulator about an auction to settle its future.

Last month, Morrisons agreed a 7 billion pound ($9.6
billion) offer from CD&R, which has former Tesco boss
Terry Leahy as a senior adviser. However, the rival consortium
led by Softbank-owned Fortress could still trump that
bid.

The fight for Britain's fourth-largest grocer after Tesco,
Sainsbury's and Asda, is the most high-profile looming
takeover amid a raft of bids and counter bids, reflecting
private equity's appetite for UK Plc.

Morrisons said that as neither bidder had declared its offer
final, it was talking to both of them and the Takeover Panel,
which governs M&A deals in the UK, about "an orderly framework
for the resolution of this competitive situation" - which would
typically be an auction.

Morrisons said shareholder meetings to vote on the CD&R
offer would be convened for around the week starting Oct. 18.

It said any auction would take place prior to these
shareholder meetings, on a date announced by the Takeover Panel.

Following completion of an auction, Morrisons shareholders
would vote on either a Fortress or a CD&R offer, depending on
which offer Morrisons' board recommended.

Morrisons said it expected a scheme document on CD&R's offer
to be posted to shareholders around Sept. 25.

CD&R's latest offer is worth 285 pence per Morrisons share -
a 60% premium to Morrisons' share price before takeover interest
emerged in mid-June.

Fortress, whose last offer was pitched at 272 pence a share,
said on Wednesday it "continues to consider its options."

Morrisons shares were trading at 291.3 pence at 1044 GMT,
indicating investors are hoping for a higher bid.

CD&R had no further comment.

AUCTION PROCESS

The Takeover Panel's standard auction structure is bidding
over a five-day period. However, if all parties are in agreement
a different structure can be used - for example bidding over
just one day.

Last month, the Takeover Panel set up an auction of British
inhaler company Vectura for suitors Philip Morris
International and U.S. private equity firm Carlyle.
However, in the event Carlyle decided not to raise its offer.

Morrisons, which trades from 497 stores and has a staff of
over 110,000, reiterated on Wednesday that in addition to the
financial terms of any offer it places "very significant
emphasis on the wider responsibilities of ownership", including
the importance of employees, customers, pension trustees and
suppliers.

Last month, the trustees of Morrisons' pension schemes
warned a takeover by either CD&R or Fortress could "materially
weaken" the security of the schemes if no additional protection
was agreed.

Morrisons is due to publish first half results on Thursday.

($1 = 0.7266 pounds)
(Reporting by James Davey
Editing by Guy Faulconbridge, Mark Potter and Jane Merriman)

More News
19 Mar 2021 09:46

BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson

BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson

Read more
18 Mar 2021 10:36

Vectura shares rise on swing to profit, GBP115 million special payout

Vectura shares rise on swing to profit, GBP115 million special payout

Read more
18 Mar 2021 07:43

Royalty income, litigation win see Vectura beat expectations

(Sharecast News) - Vectura reported a 6.9% improvement in its total revenue on Thursday, to £190.6m, driven by development services and a surge in income from royalties.

Read more
11 Mar 2021 16:13

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
5 Mar 2021 12:29

Vectura delays results because of KPMG staff shortage

(Sharecast News) - Vectura delayed the publication of its annual results after KPMG asked for more time to audit the accounts because of a staff shortage caused by Covid-19.

Read more
2 Mar 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
22 Jan 2021 09:32

LONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec

LONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec

Read more
12 Jan 2021 10:13

Vectura Forecasts 2020 Earnings To Top Board Expectations

Vectura Forecasts 2020 Earnings To Top Board Expectations

Read more
12 Jan 2021 08:16

Vectura reports 'strong' operational performance in 2020

(Sharecast News) - Inhaled medicines-focussed pharmaceutical company Vectura Group updated the market on its trading on Tuesday, saying it expected revenue and adjusted EBITDA for 2020 to be ahead of board expectations, following the fourth quarter approval of VR315 (US), or generic 'Advair', alongside Hikma.

Read more
30 Dec 2020 19:10

UK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle

UK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle

Read more
29 Dec 2020 12:04

Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation

Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation

Read more
29 Dec 2020 10:04

Glaxo not seeking re-hearing in Ellipta litigation, says Vectura

(Sharecast News) - Vectura said on Tuesday that GlaxoSmithKline has not sought to petition the US Court of Appeals for a re-hearing in the companies' ongoing litigation over GSK's Ellipta inhalers.

Read more
18 Dec 2020 17:08

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 10:45

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.